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1. Introduction 
Cystic fibrosis (CF) is the most common fatal autosomal recessive disorder in the white 
population with a frequency of 1 in 2500 live births. Inherited defects in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene result in abnormal regulation of salt 
and water movement across membranes. The overall feature of CF is that secretions are 
dehydrated due to water deprivation of luminal surfaces. This is true for the sino-
pulmonary tract, biliary tree and for reproductive tubes (vas deferens and fallopian tubes). 
Lung involvement is the main cause of morbidity and mortality, but this abnormal gene 
results in a multisystem disease affecting the liver, pancreas, sinuses, bones and 
reproductive system. Since its recognition in 1938 when life expectancy was 6 months 
(Davis, 2006), advances in medicine and a multidisciplinary team approach to patient care 
have increased the life expectancy of this condition such that children born today could 
expect to reach their 50s (Dodge et al., 2007; UK CF Trust 2009; USCF foundation 2009). The 
changing course of the disease has resulted in increasing relevance of other organ systems 
such as the liver. 
2. Epidemiology of CF Liver Disease 
The incidence of CF liver disease (CFLD) varies significantly among previous studies 
ranging from 5-30%. This is probably due to variations in definition.  
On the whole, CFLD can be classified into 3 stages: 
1. Biochemical – manifested by impaired liver enzymes 
2. Structural – as increased bile content in the liver tissues or fatty infiltration visualised 
on liver ultrasound studies 
3. Decompensated liver disease – which includes portal hypertension, hypoalbuminaemia, 
ascites and impaired coagulation. 
The authors of this chapter propose to call ‘clinically significant disease’ as hepatic 
abnormalities that necessitate treatment by pharmacological and non-pharmacological 
methods. 
In one study by Nash et al (2008), 30% of CF patients were found to be affected by clinically 
significant CFLD. Clinically significant disease in this study was defined as biochemical 
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abnormalities manifesting with raised liver enzymes and ultrasonographic evidence of 
structural changes, but not necessarily liver cirrhosis.  
Post mortem analysis suggested that focal abnormalities in the liver tissues are commoner 
than was previously thought occurring in 25-50% of CF patients (Gaskin et al., 1988; Nagel 
et al., 1989). 
The prevalence of CFLD changes with age. Unlike most CF-related complications, CFLD 
appears to decrease with age. The reason for this is not clear. In one study by Scott-Jupp et al 
(1991) on 1100 CF patients in the South and West of England, the prevalence of CFLD - as 
judged by the presence of an enlarged liver or spleen (or both) - was 4.2%. The age-related 
prevalence rose to a peak in adolescence, and then fell in patients over 20 years old. The 
authors concluded that the decrease in prevalence was not due to drop-out of those who 
died of CFLD as the proportion of fall in incidence was much greater than the expected 
mortality rate from CFLD.  
Other studies have also found increasing prevalence with age through childhood to mid-
adolescence with no significant increase thereafter (Colombo, 2007). 
The prognosis of patients with a well-established CFLD also varies. Herrmann et al (2011) 
reported that 7.9% of patients over the age of 40 have portal hypertension. But with a 7 year 
median follow up, only 28% went on to develop ascites or variceal bleeding, and liver 
failure was a late event. Median survival after a first variceal bleed is 8.4 years. This  favours 
well when compared to the general cirrhotic population where 1 year survival is only 34%. 
Hence in the absence of other markers of decompensated liver disease, bleeding may not 
necessarily be a marker of poor prognosis (Colombo, 2007). 
Older studies suggested a much more benign course, but it is now the 3rd most common 
cause of death after ventilatory failure and organ transplant complications. It is therefore an 
important cause for concern. The overall mortality rate is reported to be 2.5% (Moyer and 
Balistreri, 2009), and is associated with a higher risk of overall mortality when compared to 
CF patients without liver disease (Gallagher et al., 2011). 
3. Pathophysiology of CFLD 
CFTR is expressed in the epithelial cells of the biliary tract, but not in the hepatic cells. The 
main feature of CFLD is destruction in the biliary duct. The impaired viscosity of bile, albeit 
expected, was not consistently reported in studies.  
Factors that enhance destruction of the biliary tree may lie in the epithelial toxicity of 
retained bile salt (Westaby, 2000). Other factors leading to the development of steatosis 
(fatty liver) are not related to defects in the CFTR gene and remains poorly understood. It 
has been attributed to malnutrition, essential fatty acid deficiency, carnitine or choline 
deficiency or insulin resistance (Moyer and Balistreri, 2009). Another presumed factor is the 
impairment of the architecture of the pancreas that shares a common exit with the common 
bile duct (Westaby, 2000). 
Development of CFLD, including portal biliary cirrhosis and multilobular cirrhosis, is 
attributable to the abnormal CFTR gene. This results in abnormal transport of Cl-, HCO3- 
and H20 at the apical membrane of cholangiocytes such that the regulation of fluid and 
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electrolyte content of bile is altered. As a result, bile is more viscous in CF patients than in 
non-CF individuals as with other mucous secretions.  
Bile flow is reduced and the obstruction of intrahepatic bile ducts causes damage to 
hepatocytes and cholangiocytes through periductal inflammation, bile duct proliferation 
and fibrosis in portal tracts. This also results in activation of hepatic stellate cells, production 
of collagen, and stimulation of bile duct epithelium to produce TFG- which is 
profibrinogenic (Moyer and Balistreri, 2009).  
Why some patients with early manifestations of CFLD go on to develop liver cirrhosis and 
why some do not remains unclear. Understanding these factors in longitudinal studies will 
help design strategies for management of early liver disease with the aim of halting its 
progression and obviating its complications.  
4. Genetics of CFLD 
More than 1500 CFTR gene mutations have been described (O’Sullivan and Freedman, 
2009), but there is no evidence of a phenotype relationship with specific mutations in the 
CFTR gene. In one study, (Duthie et al., 1992) they did not identify a difference in the 
frequency of Delta F 508, G551 or R553X mutations and the presence of CFLD.  
However the same group found that several human lymphocyte antigens (HLA) subtypes 
were more prevalent in patients with CFLD compared to those without (Duthie et al., 1995).  
Genetics was assumed to play a role not only in the emergence of CFLD but also in its 
prognosis. However despite several studies reviewed by Moyer and Balistreri (2009), it 
remains unclear why only a small proportion of CF patients might develop liver disease, or 
why there was such variability in severity.  
Genetic modifiers may be one way to answer this question. Modifier genes have shown to 
play a role by increasing susceptibility to the development of CFLD by up-regulating 
inflammation, fibrosis or oxidative stress. Identifying these genetic modifiers may allow 
identification of CF patients at risk of developing CFLD and thus allow early use of 
prophylactic measures (Colombo, 2007). ACE, SERPINA, CSTP1, MBL2, TGF-1 have all 
been identified as potential gene modifiers but only the SERPINA 1 Z allele has been found 
to be strongly associated with CFLD and portal hypertension (Bartlett et al., 2009). 
5. Hepatic manifestations in cystic fibrosis 
There is a broad spectrum of hepatic manifestations in cystic fibrosis as described in Table 1 
(Colombo, 2007). Of those described the most clinically relevant in CF is focal biliary 
cirrhosis which may extend into multilobular biliary cirrhosis. 
The incidence of impaired liver enzymes is high, affecting around 65% of patients with CF 
(Bhardwaj et al., 2009). Frequently these abnormalities may be transient and could relate to 
drug treatments or intercurrent infections (Moyer and Balistreri, 2009). The majority will not 
progress to clinically significant disease despite elevations of serum alanine 
aminotransferase, aspartate transferase or gamma-glutamyl transferase of up to 2.5x the 
upper limit of normal (Herrmann et al., 2010). 
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Type of lesion  Clinical manifestation Frequency (%) 
Specific alterations ascribed to the 
underlying CFTR defect  
Focal biliary cirrhosis  20–30 
 Multilobular biliary cirrhosis 10 
 Portal hypertension  2–5 
 Neonatal cholestasis  Rare 
 Sclerosing cholangitis  Rare 
 Micro-gallbladder  30 
 Cholelithiasis  15 
Lesions of iatrogenic origin  Liver steatosis  23–67 
 Drug hepatotoxicity  Undefined 
Lesions reflecting the effects of a 
disease process that occurs outside 
the liver  
Hepatic congestion  Rare 
 Common bile duct stenosis  Rare 
Table 1. Major hepatic manifestations in cystic fibrosis (adapted from Colombo, 2007) 
Steatosis is currently considered benign in cystic fibrosis with no evidence of progression to 
cirrhosis, portal hypertension or hepatic decompensation (Debray et al., 2011), while 
gallbladder abnormalities such as microgallbladder and cholelithiasis are frequently 
asymptomatic and detected on ultrasound requiring no intervention (Moyer and Balistreri, 
2009). These hepatic manifestations can however contribute to post prandial abdominal 
discomfort, abdominal pain and fatigue in CF patients. Abdominal pain and fatigue are 
highly common in CF patients occurring in 77% (Jarad, 2009) and 87% (Sarfaraz et al., 2010) 
of patients respectively in the authors’ unit. 
Development of liver cirrhosis is less common, occurring in up to 30% of patients. This 
includes focal biliary cirrhosis with around 10% of CF patients developing multilobular 
biliary cirrhosis. Fewer still progress to liver failure and portal hypertension which can be 
associated with hypersplenism and gastro-oesophageal varices (Colombo, 2007).  
Variceal bleeding in well established CFLD occurs in 30% of all cases. However it should be 
regarded as a rare complication in the adult CF population.  
This cohort with cirrhosis and established portal hypertension are also at increased risk of 
developing hypoglycemia, malnutrition, hepatic osteodystrophy and worsening pulmonary 
status through hepato-splenomegaly and ascites-induced diaphragmatic splinting and 
intrapulmonary shunting (Colombo, 2007). 
6. Investigations 
No single reliable test is available to diagnose CFLD. Diagnosis thus relies on a combination 
of clinical assessment, liver biochemistry and other investigations. Table 2 gives proposed 
diagnostic criteria which incorporate these (Debray et al., 2011). 
Hepatomegaly is often how CFLD is detected through routine examination, however, in 
isolation this is rarely associated with advanced liver disease. The slight enlargement of the 
liver size as well as the descending edge of the liver can be due to a combination of chronic 
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lung sepsis and lung hyperinflation both of which are common in patients with CF lung 
disease.  
 
Consider CFLD if at least 2 of the following are present: 
 Hepatomegaly confirmed by ultrasonography (US) 
 > 2cm below the costal margin below the midclavicular line 
 and/or splenomegaly on US 
 Abnormal liver function tests above the upper limit of normal 
 transaminases (AST and ALT) and GGT 
 on at least 3 consecutive occasions over 12 months 
 and other causes of liver disease excluded 
 US evidence of liver involvement, portal hypertension or biliary 
abnormalities 
 Positive liver histology (biopsy may be helpful where diagnostic 
uncertainty exist)  
Table 2. Diagnostic Criteria for CFLD (Debray et al., 2011) 
Each individual element of these criteria has their limitations when considered in isolation. 
Abnormal biochemistry as previously discussed can occur frequently and often transiently. 
The chronic use of prophylactic oral antibiotics such as flucloxacillin in patients with chronic 
lung infection of Staphylococcus aureus may account for this. Also, the administration of 
beta-lactam antibiotics for acute pulmonary exacerbation is known to be associated with 
transient increases in liver enzymes. There is thus a low sensitivity for raised liver enzymes 
without abnormal radiology and abnormal histology. In addition some patients with 
multilobular biliary cirrhosis may have normal liver biochemistry (Colombo, 2007). 
Ultrasonography is non-invasive and inexpensive. It can be useful in distinguishing 
between fibrosis, cirrhosis, ductal abnormalities and fatty infiltration (Colombo, 2007). The 
additional use of duplex scanning also allows detection of portal hypertension and 
portosystemic collaterals (Herrmann et al., 2010). Changes seen on US tests are more specific 
than clinical or biochemical abnormalities, with US abnormalities often preceding these 
changes. However, a normal scan does not exclude the development of future disease. The 
test is limited by both intra and interobserver variability in sonographic assessment with a 
positive predictive value of a normal US of only 33% and a sensitivity of 57% (Debray et al., 
2011).  
Williams et al (1995) devised and validated a scoring system for the severity of CFLD. The 
scoring system included the appearance of liver parenchyma, liver edge and periportal 
fibrosis. The score was found to distinguish transient liver disease from well established 
disease. The scoring system also identified sub-groups of patients who were regarded to 
have a pre-cirrhotic liver. A prospective prognostic evaluation of this scoring system has not 
yet been performed.  
Magnetic resonance imaging (MRI) is emerging as an important investigation of the 
abdomen in CF patients (Figure 1). In a case-control study, we found that the pancreas was 
absent in CF patients with and without diabetes compared to age matched non-CF patients 
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with Type I diabetes mellitus (Sequeiros et al., 2010). In another study we also reported that 
the spleen size, as measured on MRI, is reduced in patients with CF-related diabetes 
compared to those without and compared to age-matched patients with type I diabetes 
without CF (Jarad et al., 2010).  
 
 
Fig. 1. MRI scan in a 24 year old lady with CFLD demonstrating liver cirrhosis, 
splenomegaly and tortuous veins on the spleen surface. 
As for the liver, MRI scan is both a sensitive and a specific diagnostic test for CFLD. MRI can 
characterize the architecture of the liver structures (Westaby, 2000). A further delineation of 
the portal and splenic vascular bed and further enhancement of the definition of the liver 
architecture could be made through magnetic resonance cholangio-pancreatography 
(MRCP).  
MRI and MRCP are non-invasive and well tolerated procedures, but the imaging remains 
too costly for the tests to become a screening procedure or to be used for follow-up purposes 
of all CF patients.  
The presence of fibrosis on liver biopsy is both diagnostic and predictive of development of 
future portal hypertension and significant liver disease (Lewindon et al., 2011). However, 
the patchy distribution of lesions found in CFLD mean this invasive test can underestimate 
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severity which limits its use (Colombo, 2007). It is thus not a routine test in many units 
unlike in chronic liver disease that is not linked to cystic fibrosis. 
These limitations mean that CFLD often remains undetected until advanced stages 
prompting the need for other investigations. Both MRI and CT imaging can be useful in 
discriminating steatosis from fibrosis. MRCP and hepatic scintigraphy may help detect extra 
and intrahepatic biliary tree abnormalities in patients without clinically apparent disease 
and aid assessment of biliary drainage (Herrmann et al., 2010). These may play an important 
role in the future of CFLD. Other potential methods include transient elastography 
(fibroscan), which measures liver stiffness in a non invasive manner, which correlates 
closely with fibrosis and biochemical markers of fibrosis. Their value in CF remains to be 
determined (Debray et al., 2011). 
A suggested approach to investigating CFLD and its initial management is shown in Figure 2. 
Diagnosis of liver failure is similarly problematic due to the maintenance of liver function 
until the terminal phase. Clotting factors and prothrombin time should be monitored at least 
annually as this may give an indication. Liver failure should be considered if PT remains 
prolonged or if factors VII, X and II remain decreased despite vitamin K supplementation 
(Debray et al., 2011). 
7. Management of CFLD 
The mainstay of treatment for CFLD currently is optimisation of nutritional status and bile 
acid therapy - ursodeoxycholic acid (UDCA). The aim of the former is to avoid vitamin 
deficiency and malnutrition, though a proven benefit in CFLD is lacking (Herrmann et al., 
2010).  
UDCA is a bile acid that was shown to increase bile flow (Renner et al., 1980) and probably 
protects the hepatocellular structures from the harmful effects of hydrophobic bile ducts 
(Hoffman et al., 1990) by displacement of toxic hydrophobic bile acids, cytoprotection and 
stimulation of biliary bicarbonate secretion (Moyer and Balistreri, 2009).  
Ultimately, the aim of UDCA is to delay progression of disease. There is evidence of 
improved liver biochemistry (Desmond et al., 2007) shortly after introducing UDCA and 
improved histological features of liver disease afterwards (Linblad et al., 1998). However, 
evidence of improved outcomes such as reduced need for transplantations or improved 
survival is lacking (Cheng et al., 2000). UCDA is widely used as it is the only available 
therapeutic agent and is generally well tolerated with few side effects. Recommended 
dosing is 20-30 mg/kg/day. 
All patients with CFLD should receive annual liver assessment. The need for the yearly 
input of a gastroenterologist or hepatologist has been suggested (Debray et al., 2011). 
Though they may request intuitive tests and aid recognition of progression to cirrhosis, as 
well as complications such as portal hypertension, there is no evidence of superior outcome 
compared to a review by an experienced CF physician. This is important as CF patients are 
frequently seen in hospital and all receive an annual CF assessment. Adding an assessment 
by another discipline need only be introduced to a selected group of patients.  
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Fig. 2. Investigation and initial management of CFLD (adapted from Debray et al., 2011). 
Abbreviations: CF, cystic fibrosis; CFLD, cystic fibrosis liver disease; LFTs, liver function 
tests (i.e. liver enzymes including alanine transaminase, alkaline phosphatase; asparate 
transaminase and gamma glutamyl transpeptidase); MRCP, magnetic resonance 
cholangiopancreatography; MRI, magnetic resonance imaging; UCDA, ursodeoxycholic 
acid; US, ultrasound. 
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8. Management of portal hypertension 
Though clear recommendations exist for non-CF patients with cirrhosis, there is no agreed 
guidance for this very different cohort of patients. Non-selective β-blockade is 
recommended, for example, which has not been evaluated in CF where lung disease may 
mean this is contraindicated. We do however use propranolol in at least 2 patients in our 
unit without significant respiratory side effects.  
Band ligation is more effective than sclerotherapy, which can also carry a risk of bleeding 
both during and following the procedure which may result in repeated general anesthesia to 
the detriment of the patient’s lung function. There is however no long term efficacy data in 
CF patients.  
In the absence of such studies, recent guidance (Debray et al., 2011) states that all patients 
with cirrhosis and splenomegaly and/or signs of hypersplenism should receive an 
oesophagogastroduodenoscopy (OGD) every 2-3 years to screen for oesophageal varices. If 
large varices are detected these should be treated with band ligation and repeated until 
eradicated. Frequency of screening may need to be increased to annually. As with non-CF 
patients an OGD may be required more urgently in the presence of GI bleeding. 
Transjugular intrahepatic portosystemic shunt (TIPSS) procedures have been used to 
achieve portal decompression to treat recurrent bleeding both pre-transplant (Colombo, 
2007) and to allow long term survival (Herrmann et al., 2010). Surgical portal systemic 
shunting has also been used to preserve liver function, but carries this risk of acute liver 
failure and hepatic encephalopathy (Debray et al., 2011). 
Rarely extra-pulmonary bleeding can occur from tortuous splenic and gastric veins (Figure 
3). The efficacy of splenectomy and partial splenectomy remains unclear, with some studies 
suggesting this could stabilize lung function and delay progression of portal hypertension 
(Herrmann et al., 2010). Other studies exist reporting accelerated decline in lung function 
and no reduction in variceal bleeding (Debray et al., 2011) and hence it is not recommended 
currently. Thrombocytopenia and leucopenia due to hypersplenism requires no specific 
therapy. 
9. Liver transplantation 
Liver transplantation in end-stage liver disease is a viable option with encouraging results. 
There is evidence of improved lung function, nutritional status and quality of life (Columbo, 
2007). Analysis of data from the United Network for Organ Sharing (UNOS) database by 
Mendezibal et al (2011) also demonstrated a survival benefit of liver transplant in CF when 
comparing those that had received a transplant to those that were still on the waiting list. 
The difference in mortality was significant in both paediatric and adult populations. Further 
analysis from UNOS shows good survival at 1 year and 5 years post transplant of 84% and 
76% respectively (Arnon et al., 2011). This represents the largest review of outcomes 
following transplants for CFLD and supports the findings of previous smaller studies 
(Friedell et al., 2003; Melzi et al., 2006; Nash et al., 2008). However, overall survival post liver 
transplant for CFLD is less than that seen  in non-CF patients who receive liver transplants 
for other indications. The most common cause of long term mortality is progression of 
pulmonary disease (Friedell et al., 2003), though haemorrhage also represents an important 
cause of death (Arnon et al., 2011). 
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Fig. 3. CT scan in a 26 year old man with CF showing signs of liver cirrhosis, splenomegaly 
and haematoma around the spleen and within the abdominal cavity due to spontaneous 
splenic rupture. The patient died 1 week later. 
The criteria and timing for liver transplantation remain uncertain. Although the criteria 
have widened with increased experience, inclusion of patients in liver transplantation needs 
to be evaluated on a patient-by-patient assessment. This is mainly because of concomitant 
lung disease, impaired nutrition (Figure 4) and of inability of some patients to withstand the 
rigor of transplant. One school of thought is that without signs of liver decompensation, 
survival is dependent on respiratory complications (Gooding et al., 2005). However, with 
other extra-hepatic benefits, earlier transplantation may be indicated. This needs to be 
weighed up against the risks associated with liver transplantation such as graft rejection and 
drug related complications (Debray et al., 2011).  
Improved management options for the complications of portal hypertension may mean that 
transplantation ought to be considered in those with evidence of hepatocellular dysfunction 
in addition to portal hypertension, or those with rapidly deteriorating lung function. Other 
suggested indications include: the development of ascites and jaundice, intractable variceal 
bleeding, hepatopulmonary and portopulmonary syndromes, severe malnutrition 
unresponsive to intensive nutritio nal support, and deteriorating quality of life related to 
liver disease (Debray et al., 2011).  
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Fig. 4. a) A 21 year old female CF patient with liver transplant. Please note that the patient 
needed per entero-gastric (PEG) feeding due to concomitant malnutrition and low body 
mass index. b) Liver transplant was successful with little complication despite significant 
lung disease as seen by widespread bronchiectasis on her CT scan of the chest done several 
months after transplant. 
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In some occasions when patients may need both lung and liver transplant, it would be 
indicated to undertake transplantation of both organs. With the shortage of donated organs, 
this decision needs to be taken carefully. However, survival is comparable for combined 
liver and lung transplantation where this is indicated (Arnon et al., 2011). 
10. Conclusion 
CFLD occurs relatively frequently and is the most common non-pulmonary cause of 
mortality.  
Improvements in the survival of cystic fibrosis patients mean that liver disease is likely to 
play an increasing role in long term morbidity and mortality. Current diagnosis relies on a 
combination of clinical examination and biochemistry, with old and new imaging 
techniques. UDCA is currently the only therapeutic option in CFLD, though its benefits on 
long term outcomes are not proven. Options addressing the complications of portal 
hypertension include TIPSS and OGD with variceal ligation. Orthostatic liver 
transplantation is also an option in end-stage liver disease with encouraging results. 
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